semaglutide risk of cancer New Science Suggests Improves CV Outcomes Beyond Weight Loss Semaglutide, Other GLP-1 Drugs Linked

Steven Gundry to explore how the gutbrain connection shapes mood, inflammation, and long-term health

Blood Supply in Healing 9/10 How new capillaries form and blood flow returns after vessel injury or ischaemia

Two-thirds of patients with insulinoma experience hypoglycemia within the first 24 hours, and nearly all experience hypoglycemia within 48 hours

Protocol 2: significant weight loss (20-25% body weight) Goal: Substantial weight reduction for health improvement Tirzepatide approach: Full escalation to 10-15 mg Expect to reach target dose by week 17-21 Weight loss at 15 mg: approximately 22.5% at 72 weeks Plateau typically occurs around weeks 60-72 Retatrutide approach: Full escalation to 8-12 mg Expect to reach target dose by week 13-17 Weight loss at 12 mg: 24.2% at 48 weeks, 28.7% at 68 weeks No plateau observed in trial data at 48 or 68 weeks For significant weight loss goals, retatrutide reaches 20%+ body weight reduction faster and ultimately achieves a higher ceiling